Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
mi
from
Dallas, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Baylor Health Care System/Sammons Cancer Center Baylor- Sammons
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
mi
from
Houston, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Tyler Cancer Center TCC
mi
from
Tyler, TX
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Tyler Cancer Center TCC
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Novartis Investigative Site
mi
from
Essen,
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Novartis Investigative Site
mi
from
Essen,
Click here to add this to my saved trials
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  2/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 2/13/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women
Status: Enrolling
Updated:  2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer
Correlation of SNP Patterns With Fine Needle Aspiration Cytomorphology in High Risk Postmenopausal Women
Status: Enrolling
Updated: 2/13/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated:  2/24/2017
Emory University Hospital Midtown
mi
from
Atlanta, GA
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated: 2/24/2017
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated:  2/24/2017
Grady Memorial Hospital
mi
from
Atlanta, GA
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated: 2/24/2017
Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated:  2/24/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated: 2/24/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Santa Monica, CA
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Washington,
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Washington,
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Fort Myers, FL
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Atlanta, GA
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Detroit, MI
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Lebanon, NH
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Buffalo, NY
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Durham, NC
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Cleveland, OH
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Greenville, SC
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Memphis, TN
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Nashville, TN
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Salt Lake City, UT
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Edmonton,
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Edmonton,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Baylor College of Medicine
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
ZNA Middelheim
mi
from
Antwerpen,
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
ZNA Middelheim
mi
from
Antwerpen,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University Of Alabama Comprehensive Cancer Cente
mi
from
Birmingham, AL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University Of Alabama Comprehensive Cancer Cente
mi
from
Birmingham, AL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
UCSF University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
UCSF University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Chicago Medicine
mi
from
Chicago, IL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Johns Hopkins University CRB1
mi
from
Baltimore, MD
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Johns Hopkins University CRB1
mi
from
Baltimore, MD
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Memorial Sloan-Kettering Cancer Center - Memorial hospital
mi
from
New York, NY
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Memorial Sloan-Kettering Cancer Center - Memorial hospital
mi
from
New York, NY
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Baylor College - Ucop
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Baylor College - Ucop
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Fred Hutchison Seattle Cancer Care Alliance
mi
from
Seattle, WA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Fred Hutchison Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Click here to add this to my saved trials